Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23535858 | 0.84 | CYP11B2 (0.58) | CYP11B2CYP11B1GABRA5IDO1CMA1 | |
| SCHEMBL3911396 | 0.84 | TP53 (0.53) | CYP11B2CYP11B1IDO1MAPTTP53 | |
| SCHEMBL14142426 | 0.83 | CYP11B2 (0.56) | CYP11B2CYP11B1GABRA5IDO1CMA1 | |
| SCHEMBL3111412 | 0.82 | CYP11B1 (0.51) | CYP11B2CYP11B1MAPTTP53LMNA | |
| SCHEMBL15507125 | 0.82 | CYP11B1 (0.61) | CYP11B2CYP11B1GABRA5IDO1CMA1 | |
| SCHEMBL28017590 | 0.81 | CYP11B2 (0.51) | CYP11B2CYP11B1GABRA5IDO1CMA1 | |
| SCHEMBL3914923 | 0.81 | CYP11B1 (0.54) | CYP11B2CYP11B1MAPTLMNAKDM4E | |
| SCHEMBL22004454 | 0.81 | CYP11B2 (0.53) | CYP11B2CYP11B1GABRA5IDO1CMA1 | |
| SCHEMBL3912721 | 0.80 | CYP11B1 (0.54) | CYP11B2CYP11B1IDO1LMNAKDM4E | |
| SCHEMBL3913086 | 0.80 | ABCC8 (0.49) | CYP11B2CYP11B1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1947086-A1 | BENZENE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | F12, F2, SERPINC1 | CYP11B2 658/4885CYP11B1 406/4885GABRA5 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.